drugset / Trial / NCT03453177

Intravenous and Oral Fosfomycin in Hospitalised Neonates With Clinical Sepsis

NCT03453177

RandomizedParallel-groupOpen-labelTreatment

Summary

Neonatal sepsis has a high risk of morbidity and mortality. The current WHO and national guidelines recommend antibiotics to which resistance is reported in neonatal populations, although the available data is limited. Research on alternative empirical regimens for neonatal sepsis which are affordable, safe and cost-effective, with a step-down oral option, is needed. AMR is an issue of global public health concern and is one of the WHO's global health priority areas. Understanding the benefits, risks, MIC capacity and PK of fosfomycin will influence global policy on the case management of neonates with sepsis in Kenya and international settings.

Timeline

Start
2018-03-15
Primary completion
2019-03-14
Completion
2019-05-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Fosfomycin Small molecule 100 mg/kg Intravenous
Background Ampicillin Unknown 50 mg/kg
Background Gentamicin Small molecule 3 mg/kg
Background Gentamicin Small molecule 5 mg/kg

Indications